Official Form 201 Voluntary Petition for Non-Individuals Filing for Bankruptcy page 1

Fill in this information to identify the case: 

United States Bankruptcy Court for the:

Northern District of Texas

(State) ☐ Check if this is an

Case number (if known): Chapter 11 amended filing

Official Form 201

Voluntary Petition for Non-Individuals Filing for 

Bankruptcy 06/22

If more space is needed, attach a separate sheet to this form. On the top of any additional pages, write the debtor’s name and the 

case number (if known). For more information, a separate document, Instructions for Bankruptcy Forms for Non-Individuals, is 

available.

1. Debtor’s Name EIGER BIOPHARMACEUTICALS, INC.

2. All other names debtor used 

in the last 8 years

None

Include any assumed names, 

trade names, and doing 

business as names

3. Debtor’s federal Employer 

Identification Number (EIN) 3 3 - 0 9 7 1 5 9 1

4. Debtor’s address Principal place of business

2155 Park Boulevard

Mailing address, if different from principal place

of business

Number Street Number Street

Palo Alto, California 94306

P.O. Box

City State Zip Code

Santa Clara County

City State Zip Code

Location of principal assets, if different from

principal place of business

County Number Street

City State Zip Code

5. Debtor’s website (URL) https://www.eigerbio.com

6. Type of debtor ☒ Corporation (including Limited Liability Company (LLC) and Limited Liability Partnership (LLP))

☐ Partnership (excluding LLP)

☐ Other. Specify: 

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 1 of 19
Debtor EIGER BIOPHARMACEUTICALS, INC. Case number (if known)

Name

Official Form 201 Voluntary Petition for Non-Individuals Filing for Bankruptcy page 2 

7. Describe debtor’s business

A. Check One:

☐ Health Care Business (as defined in 11 U.S.C. § 101(27A))

☐ Single Asset Real Estate (as defined in 11 U.S.C. § 101(51B))

☐ Railroad (as defined in 11 U.S.C. § 101(44))

☐ Stockbroker (as defined in 11 U.S.C. § 101(53A)) 

☐ Commodity Broker (as defined in 11 U.S.C. § 101(6))

☐ Clearing Bank (as defined in 11 U.S.C. § 781(3))

☒ None of the above

B. Check all that apply:

☐ Tax-exempt entity (as described in 26 U.S.C. § 501)

☐ Investment company, including hedge fund or pooled investment vehicle (as defined in 15 U.S.C. 

§ 80a-3) 

☐ Investment advisor (as defined in 15 U.S.C. § 80b-2(a)(11))

C. NAICS (North American Industry Classification System) 4-digit code that best describes debtor. See

 http://www.uscourts.gov/four-digit-national-association-naics-codes . 

3254

8. Under which chapter of the 

Bankruptcy Code is the 

debtor filing?

A debtor who is a “small

business debtor” must check 

the first sub- box. A debtor as 

defined in § 1182(1) who 

elects to proceed under 

subchapter V of chapter 11 

(whether or not the debtor is 

a “small business debtor”) 

must check the second subbox

Check One:

☐ Chapter 7

☐ Chapter 9

☒ Chapter 11. Check all that apply:

☐ The debtor is a small business debtor as defined in 11 U.S.C. § 101(51D), and its aggregate 

noncontingent liquidated debts (excluding debts owed to insiders or affiliates) are less than 

$3,024,725. If this sub-box is selected, attach the most recent balance sheet, statement of 

operations, cash-flow statement, and federal income tax return or if any of these documents do 

not exist, follow the procedure in 11 U.S.C. § 1116(1)(B).

☐ The debtor is a debtor as defined in 11 U.S.C. § 1182(1), its aggregate noncontingent liquidated 

debts (excluding debts owed to insiders or affiliates) are less than $7,500,000, and it chooses to 

proceed under Subchapter V of Chapter 11. If this sub-box is selected, attach the most recent 

balance sheet, statement of operations, cash-flow statement, and federal income tax return, or if 

any of these documents do not exist, follow the procedure in 11 U.S.C. § 1116(1)(B). 

☐ A plan is being filed with this petition.

☐ Acceptances of the plan were solicited prepetition from one or more classes of creditors, in 

accordance with 11 U.S.C. § 1126(b). 

☒ The debtor is required to file periodic reports (for example, 10K and 10Q) with the Securities and 

Exchange Commission according to § 13 or 15(d) of the Securities Exchange Act of 1934. File 

the Attachment to Voluntary Petition for Non-Individuals Filing for Bankruptcy under Chapter 11 

(Official Form 201A) with this form. 

☐ The debtor is a shell company as defined in the Securities Exchange Act of 1934 Rule 12b-2. 

☐ Chapter 12

9. Were prior bankruptcy cases

filed by or against the debtor 

within the last 8 years?

If more than 2 cases, attach a 

separate list.

☒ No

☐ Yes.

District

When MM/DD/YYYY Case number

District When Case number

MM/DD/YYYY

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 2 of 19
Debtor EIGER BIOPHARMACEUTICALS, INC. Case number (if known)

Name

Official Form 201 Voluntary Petition for Non-Individuals Filing for Bankruptcy page 3 

10. Are any bankruptcy cases 

pending or being filed by a 

business partner or an

affiliate of the debtor?

List all cases. If more than 1, 

attach a separate list.

☐ No

☒ Yes. Debtor See Attached Schedule 1 Relationship 

District

When

Case number, if known _______________________ MM / DD / YYYY

11. Why is the case filed in this 

district?

Check all that apply:

☒ Debtor has had its domicile, principal place of business, or principal assets in this district for 180 days 

immediately preceding the date of this petition or for a longer part of such 180 days than in any other district.

☐ A bankruptcy case concerning debtor's affiliate, general partner, or partnership is pending in this district.

12. Does the debtor own or have 

possession of any real 

property or personal property 

that needs immediate 

attention?

☒ No

☐ Yes. Answer below for each property that needs immediate attention. Attach additional sheets if needed.

Why does the property need immediate attention? (Check all that apply.) 

☐ It poses or is alleged to pose a threat of imminent and identifiable hazard to public health or

safety.

What is the hazard?

☐ It needs to be physically secured or protected from the weather.

☐ It includes perishable goods or assets that could quickly deteriorate or lose value without attention 

(for example, livestock, seasonal goods, meat, dairy, produce, or securities-related assets or 

other options).

☐ Other 

Where is the property?

Number Street

City State Zip Code

Is the property insured?

☐ No

☐ Yes. Insurance agency

Contact name

Phone

Statistical and administrative information

13. Debtor's estimation of 

available funds 

Check one:

☒ Funds will be available for distribution to unsecured creditors.

☐ After any administrative expenses are paid, no funds will be available for distribution to unsecured creditors.

14. Estimated number of 

creditors (on a 

consolidated basis)

☐ 1-49 ☐ 1,000-5,000 ☐ 25,001-50,000

☐ 50-99 ☐ 5,001-10,000 ☐ 50,001-100,000

☒ 100-199 ☐ 10,001-25,000 ☐ More than 100,000

☐ 200-999

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 3 of 19
Debtor EIGER BIOPHARMACEUTICALS, INC. Case number (if known)

Name

Official Form 201 Voluntary Petition for Non-Individuals Filing for Bankruptcy page 4 

15. Estimated assets (on a

consolidated basis)

☐ $0-$50,000 ☐ $1,000,001-$10 million ☐ $500,000,001-$1 billion

☐ $50,001-$100,000 ☒ $10,000,001-$50 million ☐ $1,000,000,001-$10 billion

☐ $100,001-$500,000 ☐ $50,000,001-$100 million ☐ $10,000,000,001-$50 billion

☐ $500,001-$1 million ☐ $100,000,001-$500 million ☐ More than $50 billion

16. Estimated liabilities (on

a consolidated basis)

☐ $0-$50,000 ☐ $1,000,001-$10 million ☐ $500,000,001-$1 billion

☐ $50,001-$100,000 ☐ $10,000,001-$50 million ☐ $1,000,000,001-$10 billion

☐ $100,001-$500,000 ☒ $50,000,001-$100 million ☐ $10,000,000,001-$50 billion

☐ $500,001-$1 million ☐ $100,000,001-$500 million ☐ More than $50 billion

Request for Relief, Declaration, and Signatures

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement in connection with a bankruptcy case can result in fines up to

$500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

17. Declaration and signature of

authorized representative of

debtor

The debtor requests relief in accordance with the chapter of title 11, United States Code, specified in this 

petition.

I have been authorized to file this petition on behalf of the debtor.

I have examined the information in this petition and have a reasonable belief that the information is true and 

correct.

 I declare under penalty of perjury that the foregoing is true and correct.

MM/ DD / YYYY

 David Apelian

Signature of authorized representative of debtor Printed name

Title Chief Executive Officer 

18. Signature of attorney  Date

Signature of attorney for debtor MM/DD/YYYY

Thomas R. Califano

Printed name

Sidley Austin LLP

Firm name

2021 McKinney Avenue, Suite 2000

Number Street

Dallas TX 75201

City

(214) 981-3300

State ZIP Code

(214) 981-3300

Contact phone

24122825 TX

Email address

Bar number State

/s/ Thomas R. Califano 4/1/2024

Executed on 4/1/2024

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 4 of 19
Fill in this information to identify the case: 

United States Bankruptcy Court for the: ,

Northern District of Texas

(State) ☐ Check if this is an

Case number (if known): Chapter 11 amended filing

Schedule 1

Pending Bankruptcy Cases Filed by the Debtor and Affiliates of the Debtor

On the date hereof, each of the entities listed below (collectively, the “Debtors”) filed a petition in the United 

States Bankruptcy Court for the Northern District of Texas for relief under chapter 11 of title 11 of the United States 

Code. The Debtors have moved for joint administration of these cases under the case number assigned to the 

chapter 11 case of Eiger BioPharmaceuticals, Inc. 

Eiger BioPharmaceuticals, Inc.

EBPI Merger Inc.

EB Pharma LLC

Eiger BioPharmaceuticals Europe Limited

EigerBio Europe Limited

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 5 of 19
MINUTES OF A MEETING OF THE 

BOARD OF DIRECTORS OF

EIGER BIOPHARMACEUTICALS, INC.

DATE: March 30, 2024

TIME: 7:30 a.m. Pacific Time

PLACE: Virtual

BOARD MEMBERS PRESENT: Tom Dietz, Ph.D.

David Apelian, M.D., Ph.D., M.B.A.

Lisa Kelly-Croswell

Jeffrey Glenn, M.D., Ph.D.

Evan Loh, M..D.

Kim Sablich

Amit Sachdev, J.D.

BOARD MEMBERS ABSENT: None

OTHERS PRESENT: Jim Vollins, J.D.

Bill Kachioff

Tom Califano, J.D., Sidley Austin LLP

Bill Curtin, J.D., Sidley Austin LLP

Carlton Fleming, J.D., Sidley Austin LLP

Anne Wallice, J.D., Sidley Austin LLP

1. CALL TO ORDER

A telephonic meeting of the Board of Directors (the “Board”) of EigerBioPharmaceuticals, Inc., a 

Delaware corporation (the “Company”), was held at the above date and time pursuant to notice duly given or

waived. Dr. Dietz presided as Chairman and Mr. Vollins acted as Secretary ofthe meeting. Dr. Dietz called the 

meeting to order and announced that the directors present constituted a quorum and that the meeting was duly

convened. At the beginning of the meeting, all attendees were present.

2. SITUATION UPDATE

The Board, management and representatives of Sidley Austin LLP discussed recent developments;

efforts to identify strategic partners, equity financing sources and other paths forward for the Company; and 

matters related to the Company’s creditors and other stakeholders. The Board also discussed the Company’s 

financial condition and prospects. Following discussion, the Board approved the resolutions attached as 

Exhibit A hereto on behalf of the Company and its subsidiaries identified therein.

Dr. Apelian and Mr. Vollins left the meeting.

3. EXECUTIVE SESSION

The Board continued to discuss strategic matters. 

4864-6120-2354 

DocuSign Envelope ID: E78EFC85-3230-43F3-923C-5555237D9E95

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 6 of 19
4. CONCLUSION

There being no further business to come before the Board, the meeting concluded at 8:15 a.m. Pacific 

Time.

Respectfully submitted:

Jim Vollins, Secretary of the Meeting

Approved:

Tom Dietz, Ph.D., Chair of the Meeting

DocuSign Envelope ID: E78EFC85-3230-43F3-923C-5555237D9E95

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 7 of 19
Exhibit A

RESOLUTIONS

OF

THE APPROVING PARTIES

OF

THE COMPANIES LISTED ON SCHEDULE I

March 30, 2024

(1) the members of the board of directors for each Company listed under Group 1 on 

Schedule I, and (2) the sole member of the Company listed under Group 2 on Schedule I (in each 

case, the “Approving Party”), of each of the entities specified on Schedule I attached hereto (each 

such entity individually, a “Company” and, collectively, the “Companies”), do hereby consent to, 

adopt and approve the following resolutions and each and every action effected thereby:

I. Chapter 11 Filing

WHEREAS, each Approving Party has considered presentations by each Company’s 

management (“Management”) and its legal and financial advisors (collectively, the “Advisors”)

regarding (a) the assets, the current and long-term liabilities, the historical performance, liquidity,

and prospects of the Companies, (b) the strategic alternatives available to the Companies, and (c) the 

potential effects of the foregoing on the Companies’ business and stakeholders (collectively, the 

“Strategic Alternatives”); and 

WHEREAS, each Approving Party has received, reviewed, considered and discussed the 

recommendations of Management and the Advisors and fully considered the Strategic Alternatives, 

including the relative risks and benefits of pursuing bankruptcy proceedings under the provisions of 

chapter 11 of title 11 of the United State Code (the “Bankruptcy Code”), and has determined that it 

is desirable and in the best interests of each Company, its creditors, its stockholders and other 

interested parties and stakeholders that each Company file a voluntary petition for relief 

(the “Petitions”) to commence a case (each, a “Bankruptcy Case” and, collectively, the “Bankruptcy 

Cases”) under chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the 

Northern District of Texas (the “Bankruptcy Court”).

RESOLVED, that each of the Companies is authorized and directed to file a Petition for 

relief under chapter 11 of the Bankruptcy Code in the Bankruptcy Court and perform any and all 

such acts as are reasonable, advisable, expedient, convenient, proper or necessary to effect the 

foregoing;

RESOLVED FURTHER, that any officer, director or other authorized person of the 

Companies or any of their delegates (each individually, an “Authorized Person” and collectively, 

the “Authorized Persons”) shall be, and each of them, acting alone, hereby is, authorized and 

empowered in the name of and on behalf of the Companies to verify, modify (as necessary or 

desirable), execute, and/or file or cause to be filed the Petitions, any ancillary documents, and all 

DocuSign Envelope ID: E78EFC85-3230-43F3-923C-5555237D9E95

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 8 of 19
other schedules, lists, motions, applications, and other papers or documents necessary or desirable in 

connection with the foregoing in such form or forms as any such Authorized Person may approve;

RESOLVED FURTHER, that each of the Authorized Persons of the Companies shall be, 

and each of them acting alone hereby is, authorized, directed and empowered, in the name of and on 

behalf of the Companies, to pay all expenses, including Advisors’ fees and retainers, taxes, consent 

payments, indemnities, and filing fees, in each case as in such Authorized Person’s or Authorized 

Persons’ judgment shall be necessary or desirable in order to fully carry out the intent and accomplish 

the purposes of the resolutions adopted herein, with all of such payments to be conclusive evidence 

of such approval and that such Authorized Person deemed the same to be so necessary, appropriate,

or advisable;

RESOLVED FURTHER, that each Authorized Person be, and hereby is, authorized, 

directed, and empowered from time to time in the name and on behalf of the Companies, to perform 

the obligations of the Companies under the Bankruptcy Code, with all such actions to be performed 

in such manner, and all such certificates, instruments, guaranties, notices, and documents to be 

executed and delivered in such form, as the Authorized Person performing or executing the same 

shall approve, and the performance or execution thereof by such Authorized Person shall be 

conclusive evidence of the approval thereof by such Authorized Person and by each Approving Party;

RESOLVED FURTHER, that each Authorized Person be, and hereby is, authorized, 

directed, and empowered from time to time in the name and on behalf of each Company, to cause the 

Companies to enter into, execute, deliver, certify, file, record, and perform such agreements, 

instruments, motions, affidavits, applications for approvals or rulings of governmental or regulatory 

authorities, certificates, or other documents, to pay all expenses, including filing fees, and to take 

such other actions as in the judgment of such Authorized Person shall be necessary, proper, or 

desirable to prosecute to a successful completion the Bankruptcy Cases and to effectuate the 

restructuring or liquidation of the Companies’ debt, other obligations, organizational form, or 

structure and ownership of the Companies, all consistent with the foregoing resolutions and to carry 

out and put into effect the purposes of these resolutions, and the transactions contemplated by these 

resolutions, their authority thereunto to be evidenced by the taking of such actions;

RESOLVED FURTHER, that the Authorized Persons be, and they hereby are, authorized 

to bind the Companies for the purposes of the resolutions herein; and

RESOLVED FURTHER, that each Approving Party has received sufficient notice of the 

actions and transactions relating to the matters contemplated by the foregoing resolutions or hereby 

waives any right to have received such notice.

II. Retention of Advisors

RESOLVED FURTHER, that each of the Authorized Persons, acting individually and with 

full power of substitution, be, and hereby is, authorized, empowered and directed to retain the 

following professionals on behalf of the Company: (i) the law firm of Sidley Austin LLP, as general 

bankruptcy counsel; (ii) the financial advisory firm of Alvarez & Marsal North America, LLC, as 

DocuSign Envelope ID: E78EFC85-3230-43F3-923C-5555237D9E95

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 9 of 19
financial advisor; (iii) the investment banking firm of SSG Advisors, LLC, as investment banker; 

(iv) Kurtzman Carson Consultants LLC, as claims and noticing agent and administrative advisor; and 

(v) any other legal counsel, accountants, financial advisors, restructuring advisors, or other 

professionals as such Authorized Person deems necessary, appropriate, or advisable to represent and 

assist the Company in carrying out its duties and responsibilities and exercising its rights under the 

Bankruptcy Code and any applicable law (including, but not limited to, the law firms filing any 

pleadings or responses) and to take any and all actions to advance the rights and obligations of the 

Company, including filing any motions, objections, replies, applications, or pleadings; and in 

connection therewith, each of the Authorized Persons be, and hereby is authorized, empowered, and 

directed, in accordance with the terms and conditions hereof, to execute appropriate retention 

agreements, pay appropriate retainers, and to cause to be filed appropriate applications for authority 

to retain such services; and 

RESOLVED FURTHER, that each of the Authorized Persons be, and hereby are, authorized and 

empowered and directed to execute and file all petitions, schedules, motions, lists, applications, pleadings, or 

other papers, and to perform such further actions and execute such further documentation that the Authorized 

Persons in their absolute discretion deem necessary, appropriate, or desirable in accordance with these 

resolutions.

III. Marketing Process and Sale

RESOLVED FURTHER, that each of the Companies, with the assistance of their Advisors, are

authorized to continue its fulsome marketing and sale process during the Chapter 11 Cases, including 

contacting, discussing, negotiating, and soliciting offers from potential bidders, including conducting any 

auction in connection therewith, in order to receive the highest or otherwise best offer for the sale of the 

Company’s Assets (collectively, the “Sale Process”);

RESOLVED FURTHER, that in the judgment of the Approving Parties, it is desirable and in the 

best interests of each Company, its interest holders, its subsidiaries, its creditors, and other parties in interest

that each Company be, and hereby is, authorized to negotiate, execute, and enter into, all required 

documentation to consummate any sale transaction for the highest or otherwise best offer for the sale of any 

assets of each Company (the “Sale Transaction(s)”) (including any stalking horse agreement, asset purchase 

agreements or any other agreements or documents evidencing any such sale (collectively, the “Purchase 

Agreement(s)”)), with such changes, additions, and modifications thereto as an Authorized Person shall 

approve;

RESOLVED FURTHER, that the Companies shall be, and hereby are, and the Authorized Persons 

shall be, and each of them, acting alone, hereby is, in the name and on behalf of the Companies, authorized, 

directed and empowered to seek entry of an order or orders authorizing entry into any Purchase Agreement(s) 

and consummation of the Sale Transaction(s) contemplated thereby, all substantially in accordance with 

documents that have been presented or will be presented to the Approving Party and/or filed with the 

Bankruptcy Court, subject to such modifications thereto as the Approving Party or Management may deem 

necessary or advisable (the approval of which to be conclusively established by the execution thereof by an 

Authorized Person);

RESOLVED FURTHER, that each of the Authorized Persons be, and hereby is, authorized and 

empowered to take any and all actions necessary or advisable to advance each Company’s rights and 

DocuSign Envelope ID: E78EFC85-3230-43F3-923C-5555237D9E95

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 10 of 19
obligations under any Purchase Agreement and/or the Sale Process, including filing of additional pleadings 

with the Bankruptcy Court; and in connection therewith, each Authorized Person, with power of delegation, 

is hereby authorized and directed to take all necessary actions in furtherance of the foregoing resolutions;

RESOLVED FURTHER, the Board hereby authorizes, adopts, approves, ratifies and confirms the 

Sale Transaction(s) and each Company’s entry into the Purchase Agreement(s), and each of the documents 

and agreements contemplated under any Purchase Agreement (the “Transaction Documents”) to which the 

Companies are a party, and the performance of the Companies’ obligations thereunder and (subject to the 

approval of the Bankruptcy Court) the consummation of the Sale Transaction(s) contemplated thereby;

RESOLVED FURTHER, that each Authorized Person hereby is authorized and empowered to 

execute and deliver any Purchase Agreement(s), any Transaction Documents and any and all certificates, 

agreements, instruments, documents and undertakings of any kind and nature contemplated thereunder to 

which each Company is to be a party or as are necessary or appropriate to consummate the Sale Transaction(s)

contemplated by any Purchase Agreement(s) and the Transaction Documents, in the name and on behalf of 

each Company, with such additions, deletions or changes therein (including, without limitation, any additions, 

deletions or changes to any schedules or exhibits thereto) as the Authorized Person executing the same shall 

approve (the execution and delivery thereof by the Authorized Person to be conclusive evidence of such 

Authorized Person’s approval of any such additions, deletions or changes);

RESOLVED FURTHER, in addition to the specific authorizations heretofore conferred upon the 

Authorized Persons, the Authorized Persons, either individually or as otherwise required by each Company’s 

governing documents and applicable law, be, and each of them hereby is, authorized to execute (under hand 

or under the common seal of the Company if appropriate), acknowledge, deliver, and file any and all 

agreements, certificates, instruments, powers of attorney, letters, forms, transfer, deeds and other documents 

on behalf of the Company relating to any Purchase Agreement(s) and the Transaction Documents.

IV. Further Actions and Prior Acts

RESOLVED FURTHER, that in addition to the specific authorizations heretofore conferred upon 

the Authorized Persons, the Authorized Persons, either individually or as otherwise required by the Company’s 

governing documents and applicable law, be, and each of them hereby is, authorized to execute (under hand 

or under the common seal of the Company if appropriate), acknowledge, deliver, and file any and all 

agreements, certificates, instruments, powers of attorney, letters, forms, transfer, deeds and other documents 

on behalf of the Company relating to the Chapter 11 Cases;

RESOLVED FURTHER, that each of the Authorized Persons, each acting individually and with full 

power of substitution be, and hereby is, authorized, empowered, and directed to execute and file all petitions, 

schedules, motions, lists, applications, pleadings, and other papers, and to perform such further actions and 

execute such further documentation that such Authorized Person in their absolute discretion deems necessary, 

appropriate, or desirable in accordance with these resolutions;

RESOLVED FURTHER, that, in addition to the specific authorizations heretofore conferred upon 

the Authorized Persons, the Authorized Persons, either individually or as otherwise required by each of the 

Company’s governing documents and applicable law, be, and each of them hereby is, authorized to take any 

and all such other and further actions, and to do all such other deeds and other things as the Company may 

lawfully do, in accordance with its governing documents and applicable law, including but not limited to, the 

negotiation, finalization, execution, acknowledgement, delivery, and filing of any and all agreements, 

certificates, instruments, powers of attorney, letters, forms, transfer, deeds, and other documents on behalf of 

DocuSign Envelope ID: E78EFC85-3230-43F3-923C-5555237D9E95

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 11 of 19
the Company, and the payment of all expenses, including but not limited to filing fees, in each case as such 

Authorized Person’s or Authorized Persons’ may, in his/her/its/their absolute and unfettered discretion 

approve, deem or determine necessary, appropriate, advisable, or desirable in order to fully carry out the intent 

and accomplish the purposes of the resolutions adopted herein; such approval, deeming, or determination to 

be conclusively evidenced by said individual taking such action or the execution thereof;

RESOLVED FURTHER, that each Approving Party has received sufficient notice of the actions and 

transactions relating to the matters contemplated by the foregoing resolutions, as may be required by the 

organizational documents of the Company, or hereby waive any right to have received such notice; and

RESOLVED FURTHER, that all acts, actions, and transactions relating to the matters contemplated 

by the foregoing resolutions done in the name of and on behalf of the Company, which acts would have been 

approved by the foregoing resolutions except that such acts were taken before the adoption of these resolutions, 

are hereby in all respects approved, confirmed and ratified as the true acts and deeds of the Company with the 

same force and effect as if each such act, transaction, agreement, or certificate had been specifically authorized 

in advance by resolution of the Approving Parties.

DocuSign Envelope ID: E78EFC85-3230-43F3-923C-5555237D9E95

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 12 of 19
SCHEDULE I

Group 1

Eiger BioPharmaceuticals, Inc.

EBPI Merger, Inc.

Eiger BioPharmaceuticals Europe Limited

EigerBio Europe Limited

Group 2

EB Pharma, LLC

DocuSign Envelope ID: E78EFC85-3230-43F3-923C-5555237D9E95

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 13 of 19
Page 4

Official Form 201A (12/15)

IN THE UNITED STATES BANKRUPTCY COURT

FOR THE NORTHERN DISTRICT OF TEXAS

DALLAS DIVISION

)

In re: ) Chapter 11

)

EIGER BIOPHARMACEUTICALS, INC. ) Case No. 24-___________(___)

)

Debtor. )

)

Attachment to Voluntary Petition for Non-Individuals Filing for Bankruptcy under Chapter 11

If any of the debtor’s securities are registered under Section 12 of the Securities Exchange Act of 1934, the SEC file 

number is 001-36183

The following financial data is the latest available information and refers to the debtor’s condition on

December 31, 2023 

Total assets $ 38,826,000

Total debts (including debts listed in 2.c., below) $ 53,139,000

Debt securities held by more than 500 holders

secured ☐ unsecured ☐ subordinated ☐ $

secured ☐ unsecured ☐ subordinated ☐ $

secured ☐ unsecured ☐ subordinated ☐ $

secured ☐ unsecured ☐ subordinated ☐ $

secured ☐ unsecured ☐ subordinated ☐ $

Number of shares of preferred stock

Number of shares of common stock 1,479,483 (as of 

December 31, 2023 (as 

adjusted to reflect the 

1-for-30 reverse stock

split effected on

January 5, 2024))

Comments, if any: 

Brief description of debtor’s business: Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical 

company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. All of the

Company’s rare disease programs in its portfolio have FDA Breakthrough Therapy designation.

List the names of any person who directly or indirectly owns, controls, or holds, with power to vote, 5% or more of the voting 

securities of debtor: 

Moshe Arkin 

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 14 of 19
IN THE UNITED STATES BANKRUPTCY COURT

FOR THE NORTHERN DISTRICT OF TEXAS

DALLAS DIVISION

)

In re: ) Chapter 11

)

EIGER BIOPHARMACEUTICALS, INC. )

)

Case No. 24-___________(___)

)

Debtor. )

)

LIST OF EQUITY SECURITY HOLDERS1

Equity Holder Address of Equity Holder Percentage of 

Equity Held

Entities Affiliated with Ameriprise 

Financial, Inc.

(includes Ameriprise Financial, Inc. 

(AFI), Columbia Management Investors 

Advisors, LLC (CIMA), and Columbia 

Seligman Technology and Information 

Fund (Fund)) 

AFI: 145 Ameriprise 

Financial Center, 

Minneapolis, MN 55474 

CIMA & Fund: 290 

Congress Street, Boston MA 

02210 

16. 90 % 

Entities Affiliated with Propel Bio 

Partners LLC 

(includes Propel Bio Partners LLC, 

Richard and Suzanne Kayne Living 

Trust DTD 01/14/1999, and Propel Bio 

Partners LLC)

1900 Avenue of the Stars, 

#1000, Los Angeles, CA 

90067 

12.10 % 

Moshe Arkin Address On File 10.09 % 

1

 This list reflects holders of five percent or more of Eiger BioPharmaceuticals, Inc.’s common stock. This list 

serves as the disclosure required to be made by the debtor pursuant to rule 1007 of the Federal Rules of Bankruptcy 

Procedure. All equity positions are based upon information supplied by the equity holders on Schedules 13D and 

13G filed by the equity holders with the U.S. Securities and Exchange Commission, and reflect equity positions 

preceding the date of commencement of these chapter 11 cases, and are as of the date of such filings. By the 

Debtors’ Emergency Motion for Entry of an Order (I) Authorizing the Debtors to (A) File a Consolidated Creditor 

Matrix and (B) File a Consolidated List of 30 Largest Unsecured Creditors; (II) Waiving the Requirement to File 

a List of Equity Security Holders; (III) Authorizing the Debtors to Redact Certain Personally Identifying 

Information; and (IV) Approving the Form and Manner of Notifying Creditors of the Commencement of the 

Chapter 11 Cases and Other Information, filed contemporaneously herewith, the debtor is requesting a waiver of 

the required under rule 1007 to file a list of all of its equity security holders. 

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 15 of 19
IN THE UNITED STATES BANKRUPTCY COURT

FOR THE NORTHERN DISTRICT OF TEXAS

DALLAS DIVISION

)

In re: ) Chapter 11

)

EIGER BIOPHARMACEUTICALS, INC. )

)

Case No. 24-___________(___)

)

Debtor. )

)

CORPORATE OWNERSHIP STATEMENT1

Pursuant to Rules 1007(a)(1) and 7007.1 of the Federal Rules of Bankruptcy Procedure, 

the following are corporations, other than a government unit, that directly or indirectly own 10% 

or more of any class of the debtor’s equity interest: 

Shareholder Approximate Percentage of Shares Held

Entities Affiliated with Ameriprise Financial, 

Inc.

(includes Ameriprise Financial, Inc., Columbia 

Management Investors Advisors, LLC, and 

Columbia Seligman Technology and 

Information Fund) 

16.90 % 

Entities Affiliated with Propel Bio Partners LLC

(includes Propel Bio Partners LLC, Richard and 

Suzanne Kayne Living Trust DTD 01/14/1999, 

and Propel Bio Partners LLC)

12.10 % 

Moshe Arkin 10.09 % 

1 All equity positions are based upon information supplied by the equity holders on Schedules 13D and 13G filed 

by the equity holders with the U.S. Securities and Exchange Commission, and reflect equity positions preceding 

the date of commencement of these chapter 11 cases, and are as of the date of such filings. 

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 16 of 19
Fill in this information to identify the case:

Debtor name: Eiger Biopharmaceuticals, Inc.

United States Bankruptcy Court for the: Northern District of Texas Dallas Division

Case number (If known): ___________  Check if this is an amended filing

Total claim, if 

partially 

secured

Deduction 

for value of 

collateral or 

setoff

Unsecured claim

1

Merck Sharp & Dohme LLC

126 East Lincoln Avenue

Rahway, NJ 07065

United States

Attn: Robert M. Davis 

Title: Chairman and Chief Executive Officer

Phone: 908-740-4000

Trade Payables $1,000,000

2

IQVIA Biotech LLC

1700 Perimeter Park Dr

Morrisville, NC 02760

United States

Attn: Mary Fisher

Title: Senior Billing Specialist, Finance Department

Phone: (919) 972-2289

Email: mfisher@iqvia.com

Trade Payables $416,879

3

SATT Conectus Alsace SAS

5 Rue Schiller

Strasbourg Bas-Rhin, 67000

France

Attn: Marc Gillmann

Title: Chairman and Chief Executive Officer

Phone: +33 (0) 3 68 41 12 60

Email: marc.gillmann@conectus.fr

Trade Payables $331,733

4

RRD International, LLC

7361 Calhoun Place, Suite 510

Rockville, MD 20855

United States

Attn: Scott Tarrant

Title: Chief Executive Officer

Phone: (301) 762-6100

Email: starrant@rrdintl.com

Trade Payables $271,725

5

Real Staffing Group

C/O Specialist Staffing Solutions, Inc.

909 Fannin Street Suite P 350

Houston, TX 77010

United States

Attn: Andrew Beach

Title: Chief Financial Officer

Email: A.beach@sthree.com

Trade Payables $159,452

6

Patheon Inc.

168 Third Avenue 

Waltham, MA 02451

United States

Attn: Marc N. Casper

Title: Chairman, President and Chief Executive Officer

Phone: (781) 622-1000

Email: marc.casper@thermofisher.com

Trade Payables $150,291

7

Biorasi LLC

18851 NE 29th Ave Suite 800

Miami, FL 33180

United States

Attn: Chris O'Brien

Title: Chief Executive Officer

Phone: (786) 388-0700

Email: cobrien@biorasi.com

Trade Payables $134,145

8

Connor Group Global Services LLC

3979 Freedom Circle

Suite 700

Santa Clara, CA 95054

United States

Attn: Jeff Pickett

Title: Founder and Chair

Phone: (650) 300-5101

Email: jeff@connorgp.com

Trade Payables $132,510

9

Sharp Packaging Services LLC

7451 Keebler Way

Allentown, PA 18106

United States

Attn: Kevin Orfan

Title: Chief Executive Officer

Phone: (610) 395-5800 

Email: whitney.beatty@sharpclinical.com

Trade Payables $105,000

10

Patheon Manufacturing Services LLC

5900 Martin Luther King Jr Hwy.

Greenville, NC 27834

United States

Attn: Marc N. Casper

Title: Chairman, President and Chief Executive Officer

Phone: (781) 622-1000

Email: marc.casper@thermofisher.com

Trade Payables $94,884

11

Trustees of the University of Pennsylvania

C/O Penn Center For Innovation

Office of the University Secretary 

1 College Hall, Room 211

Philadelphia, PA 19104-6303

United States

Attn: Ramanan Raghavendran

Title: Chair

Phone: (215) 898-7005

Email: ofcsec@pobox.upenn.edu

Trade Payables $94,677

12

Yuki Gosei Kogyo Co Ltd

10-4, Nihonbashi-Ningyocho 3-Chome

Chuo-Ku

Tokyo, 103-0013

Japan

Attn: Seiichiro Matsumoto

Title: President/CEO/Executive Officer

Phone: (212) 318-2000

Email: Y-hiraoka@yuki-gosei.co.jp

Trade Payables $81,250

13

ICON Clinical Research Limited

South County Business Park

Leopardstown

Dublin 18, 

Ireland

Attn: Kyle McAllister

Title: Executive Director, Business Development

Phone: (402) 875-0211

Email: Kyle.McAllister@iconplc.com

Trade Payables $76,286

14

Bachem

Bachem Americas, Inc

1271 Avenida Chelsea

Vista, CA 92081

United States

Attn: Lara Hurant

Title: Project Manager

Phone: (888) 422-2436

Email: lara.hurant@bachem.com

Trade Payables $60,000

15

Fisher Clinical Services, Inc.

13741 Collections Center Drive

Chicago, IL 60693

United States

Attn: Marc N. Casper

Title: Chairman, President and Chief Executive Officer

Phone: (781) 622-1000

Email: marc.casper@thermofisher.com

Trade Payables $59,454

16

Kilpatrick Townsend and Stockton LLP

1100 Peachtree Street NE Suite 2800

Atlanta, GA 30309

United States

Attn: J. Henry Walker IV

Title: Chair and Chief Executive Officer

Phone: (404) 815-6050

Email: hwalker@ktslaw.com

Trade Payables $58,126

Official Form 204

Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 30 Largest Unsecured Claims and Are Not Insiders

12/15

A list of creditors holding the 30 largest unsecured claims must be filed in a Chapter 11 or Chapter 9 case. Include claims which the debtor disputes. Do not include claims by any person or entity who 

is an insider, as defined in 11 U.S.C. § 101(31). Also, do not include claims by secured creditors, unless the unsecured claim resulting from inadequate collateral value places the creditor among the 

holders of the 30 largest unsecured claims.

Name of creditor and complete mailing 

address, including zip code

Name, telephone number, and email address of creditor 

contact

Nature of the claim 

(for example, trade 

debts, bank loans, 

professional 

services, and

government 

contracts)

Indicate if claim 

is contingent, 

unliquidated, or 

disputed

Amount of unsecured claim

If the claim is fully unsecured, fill in only unsecured 

claim amount. If claim is partially secured, fill in total 

claim amount and deduction for value of collateral or 

setoff to calculate unsecured claim.

1

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 17 of 19
Total claim, if 

partially 

secured

Deduction 

for value of 

collateral or 

setoff

Unsecured claim

Name of creditor and complete mailing 

address, including zip code

Name, telephone number, and email address of creditor 

contact

Nature of the claim 

(for example, trade 

debts, bank loans, 

professional 

services, and

government 

contracts)

Indicate if claim 

is contingent, 

unliquidated, or 

disputed

Amount of unsecured claim

If the claim is fully unsecured, fill in only unsecured 

claim amount. If claim is partially secured, fill in total 

claim amount and deduction for value of collateral or 

setoff to calculate unsecured claim.

17

IQVIA Inc.

1700 Perimeter Park Dr

Morrisville, NC 02760

United States

Attn: Debora Mesquita

Title: Associate Clinical Project Management Director

Phone: +55 16 3306 7351

Email: debora.mesquita@iqvia.com

Trade Payables $55,612

18

Frontage Laboratories, Inc.

700 Pennsylvania Drive

Exton, PA 19341

United States

Attn: Dr. Abdul Mutlib

Title: Chief Executive Officer

Phone: (610) 232-0100

Email: AccountsReceivable@frontagelab.com

Trade Payables $52,865

19

CPA Global Limited

2318 Mill Road, 12th Floor

Alexandria, VA 22314

United States

Attn: Jerre Stead

Title: Executive Chairman and Chief Executive Officer

Phone: (703) 739-2234

Trade Payables $48,251

20

Fisher BioServices, Inc.

14665 Rothgeb Drive

Rockville, MD 20850

United States

Attn: Marc N. Casper

Title: Chief Executive Officer

Phone: (301) 315-8460

Email: paul.abel@thermofisher.com

Trade Payables $39,479

21

Eurofins Lancaster Laboratories, Inc.

2425 New Holland Pike

Lancaster, PA 17601

United States

Attn: Dr. Gilles G. Martin

Title: Chairman of the Board and Chief Executive Officer

Phone: (717) 656-2300

Email: KatelynMartin@eurofinsUS.com

Trade Payables $38,795

22

Intsel Chimos

1 Rue Royale- Batiment D

Saint-Cloud, 92210

France

Attn: Corinne Truffault

Title: Chief Executive Officer

Phone: +33 1 49 11 66 80

Email: corinne@intselchimos.com

Trade Payables $38,295

23

Richard Franco

C/O TRG Communications LLC

Address On File

Attn: Richard Franco

Title: Consultant

Phone: (919) 606-2908

Email: richfranco34@gmail.com

Trade Payables $30,745

24

Addison Whitney

11525 N Community House Rd Ste 400

Charlotte, NC 28277

United States

Attn: Natasha Kempf

Title: Director of Finance

Phone: (704) 697-4020

Email: nkempf@addisonwhitney.com

Trade Payables $28,951

25

Oracle America Inc.

2300 Oracle Way

Austin, TX 78741

United States

Attn: Safra A. Catz

Title: Chief Executive Officer

Phone: (737) 867-1000

Email: safra.catz@oracle.com

Trade Payables $28,638

26

Partners4access B.V.

Boslaan 18 

Hilversum 1217 CV, 

Netherlands

Attn: Sophie Schmitz

Title: Managing Partner

Phone: 31 6 55 88 71 96

Trade Payables $23,375

27

Broadridge ICS

5 Dakota Drive, Suite 300

Lake Success, NY 11042

United States

Attn: Tim Gokey

Title: Chief Executive Officer

Phone: (800) 353-0103

Email: remittance@broadridge.com

Trade Payables $21,562

28

Integrichain, Inc.

8 Penn Center, 3rd Flr.

1628 JFK Blvd.

Philadelphia, PA 19103

United States

Attn: Josh Halpern

Title: Co-Founder and Chief Executive Officer

Phone: (609) 806-5005

Email: jhalpern@integrichain.com

Trade Payables $18,120

29

Clinigen Inc.

Idis House

Churchfield Road

Weybridge Surrey, KT46 8DB

United Kingdom

Attn: Jerome Charton

Title: Chief Executive Officer

Phone: +44 (0) 1932 824000

Trade Payables $16,991

30

Accenture LLP

500 W Madison St

Chicago, IL 60661-2592

United States

Attn: Julie Sweet

Title: Chief Executive Officer

Phone: (312) 693-0161

Email: karla.e.falco@accenture.com

Trade Payables $16,446

2

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 18 of 19
Fill in this information to identify the case and this filing:

Debtor Name EIGER BIOPHARMACEUTICALS, INC.

United States Bankruptcy Court for the: Northern District of Texas

(State)

Case number (If known):

Official Form 202

Declaration Under Penalty of Perjury for Non-Individual Debtors 12/15

An individual who is authorized to act on behalf of a non-individual debtor, such as a corporation or partnership, must sign and 

submit this form for the schedules of assets and liabilities, any other document that requires a declaration that is not included in 

the document, and any amendments of those documents. This form must state the individual’s position or relationship to the 

debtor, the identity of the document, and the date. Bankruptcy Rules 1008 and 9011.

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property 

by fraud in connection with a bankruptcy case can result in fines up to $500,000 or imprisonment for up to 20 years, or both. 18 

U.S.C. §§ 152, 1341, 1519, and 3571.

Declaration and signature

I am the president, another officer, or an authorized agent of the corporation; a member or an authorized agent of the 

partnership; or another individual serving as a representative of the debtor in this case.

I have examined the information in the documents checked below and I have a reasonable belief that the information is true 

and correct:

☐ Schedule A/B: Assets-Real and Personal Property (Official Form 206A/B)

☐ Schedule D: Creditors Who Have Claims Secured by Property (Official Form 206D)

☐ Schedule E/F: Creditors Who Have Unsecured Claims (Official Form 206E/F)

☐ Schedule G: Executory Contracts and Unexpired Leases (Official Form 206G)

☐ Schedule H: Codebtors (Official Form 206H)

☐ Summary of Assets and Liabilities for Non-Individuals (Official Form 206Sum)

☐ Amended Schedule

☒ Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 30 Largest Unsecured Claims and Are Not Insiders

(Official Form 204)

☒ Other document that requires a declaration List of Equity Security Holders and Corporate Ownership Statement

I declare under penalty of perjury that the foregoing is true and correct.

Executed on

MM/ DD/YYYY Signature of individual signing on behalf of debtor 

David Apelian

Printed name

Chief Executive Officer

Position or relationship to debtor

Official Form 202 Declaration Under Penalty of Perjury for Non-Individual Debtors

4/1/2024

Case 24-80040-11 Doc 1 Filed 04/01/24 Entered 04/01/24 08:46:13 Desc Main

Document Page 19 of 19